Fulvestrant (ICI 182,780): High-Affinity Estrogen Receptor Antagonist for ER-Positive Breast Cancer Research

Executive Summary: Fulvestrant (ICI 182,780) is a high-affinity, specific estrogen receptor (ER) antagonist that binds and degrades ER in ER-positive breast cancer cells, leading to attenuation of ER-mediated signaling pathways (APExBIO product page). It exhibits an IC50 of 9.4 nM in vitro, efficiently downregulates MDM2 protein, and enhances sensitivity to chemotherapeutic agents like doxorubicin and paclitaxel. Commonly deployed at 1–10 μM for up to 66 hours in vitro or as a 250 mg monthly injection in clinical settings, Fulvestrant is central to studies on endocrine therapy resistance and receptor-mediated cell cycle arrest. Its biochemical properties enable robust integration into translational research and advanced oncology workflows (Wang et al. 2021).

Biological Rationale

Estrogen receptors (ERα, ERβ) are nuclear hormone receptors that regulate transcriptional programs critical for proliferation and survival in ER-positive breast cancer cells. Activation of ER drives expression of genes involved in cell cycle progression, anti-apoptotic signaling, and resistance to cytotoxic drugs (review). Fulvestrant was developed to directly antagonize ER signaling, providing a tool for dissecting the dependencies of cancer cells on estrogen-driven pathways.

Endocrine resistance remains a principal challenge in advanced breast cancer therapy. Experimental models demonstrate that Fulvestrant, by degrading ER, can circumvent some mechanisms of resistance observed with selective estrogen receptor modulators (SERMs) and aromatase inhibitors. The compound’s ability to downregulate MDM2, a ubiquitin ligase that negatively regulates p53, further enhances its therapeutic rationale by promoting apoptosis and senescence in cancer cells (mechanistic insight).

Mechanism of Action of Fulvestrant (ICI 182,780)

Fulvestrant (ICI 182,780) is a steroidal antiestrogen that binds competitively to the ligand-binding domain of ERα and ERβ with high affinity (IC50: 9.4 nM in cell-based assays) (APExBIO). Upon binding, Fulvestrant induces a conformational change that promotes ER degradation via the proteasome pathway. This leads to depletion of functional ER in both cytoplasmic and nuclear compartments.

The loss of ER interrupts transcription of estrogen-responsive genes, resulting in: (i) cell cycle arrest at G1, (ii) decreased expression of pro-survival factors like MDM2, and (iii) increased apoptosis and cellular senescence. In vitro, these effects are observed in ER-positive human breast cancer cell lines (e.g., MCF7, T47D) after 24–66 hours of treatment at concentrations of 1–10 μM (translational review).

Evidence & Benchmarks

• Fulvestrant binds to human ERα with an IC50 of 9.4 nM in competitive binding assays (APExBIO).
• Treatment with Fulvestrant (1–10 μM, 24–66 h) leads to near-complete ER protein degradation in MCF7 and T47D cells, confirmed by immunoblot (ER-EGFP Review).
• Fulvestrant downregulates MDM2, sensitizing ER+ breast cancer cells to chemotherapeutic agents such as doxorubicin, paclitaxel, and etoposide (qPCRMaster review).
• In vivo, administration in nude mice with human breast cancer xenografts inhibits tumor growth significantly compared to vehicle controls (acenocoumarolshop synthesis).
• Clinically, monthly 250 mg intramuscular injections of Fulvestrant are approved for postmenopausal women with advanced ER+ breast cancer progressing after prior endocrine therapy (Wang et al. 2021).
• In immune modulation studies, Fulvestrant blocks estrogen-induced normalization of CD4+ T lymphocyte proliferation following hemorrhagic shock in rats (5 μg/mL ConA, 48 h incubation) (Wang et al. 2021, Figure 1).

Applications, Limits & Misconceptions

Fulvestrant is widely utilized in research on ER-positive breast cancer, particularly to model mechanisms of endocrine resistance, evaluate ER-targeted combination therapies, and dissect the roles of ER signaling in cell survival and immune modulation. It is also a reference antagonist in studies requiring complete ER blockade (A1428 kit).

This article extends the findings reviewed in ER-EGFP by directly mapping experimental conditions and linking molecular outcomes to mechanistic benchmarks. It also clarifies translational relevance beyond ER-MScarlet by detailing immune context and workflow integration.

Common Pitfalls or Misconceptions

• Fulvestrant is not effective in ER-negative breast cancer cell lines; efficacy depends on ER protein presence and function (reference).
• The compound is insoluble in water; DMSO (≥30.35 mg/mL) or ethanol (≥58.9 mg/mL) must be used for stock solutions (APExBIO).
• Fulvestrant does not block rapid, non-genomic estrogen signaling mediated by GPR30; blockade is specific to nuclear ERα/ERβ (Wang et al. 2021).
• In vivo efficacy and safety profiles observed in mice do not always translate directly to human or other animal models (qPCRMaster review).
• Fulvestrant (ICI 182,780) is frequently confused with similar-sounding compounds (e.g., fulvestrin, fulvesterant); only ICI 182,780 is approved for clinical and research use as described (APExBIO).

Workflow Integration & Parameters

For in vitro assays, Fulvestrant is typically dissolved in DMSO or ethanol and used at final concentrations of 1–10 μM, with treatment durations of 24–66 hours. Stock solutions are stable for several months at -20°C. Solubility can be enhanced by warming to 37°C and applying ultrasonic agitation. In vivo, Fulvestrant is administered in preclinical models (e.g., nude mice) via injection, dosed according to tumor burden and pharmacokinetic studies (ERBB-2 dossier).

Clinically, Fulvestrant is approved as a 250 mg intramuscular injection monthly for postmenopausal women with advanced ER+ breast cancer. Experimental protocols should always match published benchmarks for concentration, solvent, and exposure time. For optimal performance, source Fulvestrant (ICI 182,780) from validated suppliers such as APExBIO (APExBIO).

Conclusion & Outlook

Fulvestrant (ICI 182,780) is a gold-standard estrogen receptor antagonist for both preclinical and clinical applications in ER-positive breast cancer research. Its mechanism is well-defined, involving high-affinity ER binding and targeted degradation, leading to potent inhibition of ER-mediated pathways. The compound’s robust evidence base supports its continued use in studies of endocrine resistance, chemosensitization, and immune modulation. Future research may further integrate Fulvestrant in combination regimens and expand its utility in immuno-oncology.

For detailed protocols, product specifications, and sourcing, refer to the official Fulvestrant (ICI 182,780) product page at APExBIO.